Clinical trials: OAG - Open-Angle Glaucoma
Glaucoma, Open-Angle, Ocular Hypertension
A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate 0.03% bimatoprost in the treatment of primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUSDI (NCT02020512)
- Testing
- 0.03% Bimatoprost
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma (POAG)
UBM Evaluation After Combined Deep Sclerectomy With Trabeculotomy in Primary Open Angle Glaucoma
Primary open-angle glaucoma is a chronic optic neuropathy that often requires surgical intervention when medical treatment fails.
- Trial name
- NCT07454447
- Testing
- Ultrasound Biomicroscopy
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Minia University Hospital
Primary Open Angle Glaucoma, Glaucoma
The Objective is to Evaluate the Anterior Chamber Angle After BANG Procedure, the Study Will Recruit 12 Patients Who Will Undergo Planned Goniectomy for Uncontrolled POAG, Anterior Segment OCT Scan Will Be Used to Evaluate the Anterior Chamber Postoperatively.
Evaluation of anterior segment using anterior segment optical coherence tomography in patients undergoing planned bent angle needle goniectomy procedure for uncontrolled open angle glaucoma.
- Trial name
- NCT06526416
- Testing
- Anterior segment optical coherence tomography
- Volunteers
- 12 people
- Sponsor
- Benha University
Pseudoexfoliation Syndrome, Pseudoexfoliation Glaucoma in Both Eyes
Real World Evidence of Xen45 Gel Implant in Pseudoexfoliation Glaucoma
The Xen implant is an ab interno device that has been shown to be effective in reducing intraocular pressure in several types of glaucoma, although the evidence in pseudoexfoliative glaucoma is limited.
- Conditions
- Pseudoexfoliation Syndrome, Pseudoexfoliation Glaucoma in Both Eyes, Open Angle Glaucoma
- Trial name
- NCT06993311
- Testing
- Xen Gel Stent implantation
- Where
- Spain
- Volunteers
- 350 people
- Sponsor
- Xerencia de Xestión Integrada de Ferrol
Primary Open Angle Glaucoma
Comparison of Retinal Nerve Fiber Layer (RNFL) Thickness Measurements by Time-Domain and Spectral-Domain OCT In Glaucoma Patients
Measurement of RNFL thickness by OCT is at a cornerstone for the correct diagnosis and monitoring of progression of glaucomatous optic neuropathy.
- Trial name
- NCT00773877
- Where
- South Korea
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Ocular Hypertension, Open-angle Glaucoma
Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension
Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution
- Trial name
- NCT02207621
- Testing
- AR-13324 Ophthalmic Solution 0.02%, Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02% BID
- Where
- United States
- Volunteers
- 756 people
- Sponsor
- Aerie Pharmaceuticals
Primary Open-angle Glaucoma
Glaukos® iStent® Trabecular Micro-Bypass Stent System In Conjunction With Cataract Surgery Postmarket Registry
The purpose of this study is to observe the safety of the Glaukos® iStent® Trabecular Micro-Bypass Stent Model GTS100 in conjunction with cataract surgery in subjects with mild to moderate open-angle glaucoma.
- Trial name
- NCT01841437
- Testing
- iStent
- Where
- 18 sites in United States
- Volunteers
- 191 people
- Sponsor
- Glaukos Corporation
Open-Angle Glaucoma, Ocular Hypertension
A Phase III Study of Brimonidine Tartrate Ophthalmic Solution, 0.15% in Patients With Open-Angle Glaucoma or Ocular Hypertension
The primary objective of this study is to compare the safety and efficacy of Brimonidine Tartrate Ophthalmic Solution, 0.15% in patients with open-angle glaucoma or ocular hypertension.
- Trial name
- NCT00061529
- Testing
- Brimonidine Tartrate Ophthalmic Solution
- Where
- United States
- Sponsor
- Alcon Research
Open-angle Glaucoma (OAG)
5-Year Postoperative Outcomes of Patients Who Completed the CREST Study
This study is designed to collect clinical data at 3, 4, and 5 years postoperatively for participants who completed the CREST Study without having secondary IOP-lowering surgery in the study eye(s).
- Trial name
- CREST-XT (NCT07480343)
- Testing
- CycloPen Micro-Interventional Cyclodialysis System, CycloPen Micro-Interventional Cyclodialysis System Post Cataract
- Where
- 10 sites in United States
- Volunteers
- 250 people
- Sponsor
- Iantrek, Inc.
Primary Open Angle Glaucoma, Acupressure
Regulation of Intraocular Pressure in Glaucoma Patients by Acupressure
The purpose of this clinical trial is to implement acupressure twice daily and monitor the changes in intraocular pressure (IOP) in patients with different levels of glaucoma.
- Trial name
- NCT05898997
- Testing
- Acupressure
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Ocular Hypertension, Open-angle Glaucoma
Double-masked Study of AR-13324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
To evaluate the ocular hypotensive efficacy and ocular and systemic safety of AR-13324 Ophthalmic Solution, 0.02% compared to the active comparator Timolol maleate Ophthalmic Solution, 0.5%
- Trial name
- Rocket-1 (NCT02207491)
- Testing
- Timolol maleate Ophthalmic Solution 0.5% BID, AR-13324 Ophthalmic Solution 0.02%
- Where
- United States
- Volunteers
- 411 people
- Sponsor
- Aerie Pharmaceuticals
Open Angle Glaucoma and Cataract
RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery.
Post-operative cystoid macular oedema (CMO) is a common complication causing visual loss following routine cataract surgery. This complication is more prevalent in eyes with excessive inflammation as they heal from surgery.
- Trial name
- CMO (NCT03292796)
- Testing
- Prostaglandins
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- Julie Dawson
Ocular Hypertension, Primary Open Angle Glaucoma
A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a single-center, cross-over comparison parallel group randomized trial designed to evaluate the efficacy and safety of Ganfort compared to Duotrav for a treatment period of 8 weeks each.
- Trial name
- NCT01168414
- Testing
- Ganfort, Duotrav
- Where
- Malaysia
- Volunteers
- 42 people
- Sponsor
- Ministry of Health, Malaysia
Open Angle Glaucoma
Micropulse Laser Trabeculoplasty (MLT) Versus Selective Laser Trabeculoplasty (SLT) for Treatment of Open Angle Glaucoma
The purpose of this study is to evaluate the effectiveness of a new laser (called Micropulse Laser Trabeculoplasty or MLT) in the treatment of glaucoma compared to the conventional laser presently used which is called selective…
- Trial name
- NCT01956942
- Testing
- Micropulse Laser Trabeculoplasty, Selective Laser Trabeculoplasty
- Where
- United States
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- David Belyea
Glaucoma Primary Open Angle
Comparison of Efficacy & Tolerability Between Ganfort vs Krytantek in Mexican Patients With Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
The objective of this phase IV clinical multi-center trial will be to compare the efficacy and safety of Ganforti® versus Krytantek®, using a cross-over design during a six month period (including a one-month wash-in period) in…
- Trial name
- NCT01737853
- Testing
- Ganforti, Krytantek
- Where
- 4 sites in Mexico
- Volunteers
- 90 people
- Sponsor
- Allergan S.A. DE C.V..
Primary Open Angle Glaucoma
Efficacy of Retinal Nerve Fiber Layer (RNFL) / Ganglion Cell Layer Thickness Ratio by RT-View Utilizing Spectral -Domain Technology as a Diagnostic Predictor of Glaucoma.
RT-View utilizes spectral domain technology to assess both RNFL and ganglion cell layer thickness. This study aims to correlate visual field defects in patients with glaucoma to both RNFL and ganglion cell layer thickness.
- Trial name
- NCT00773123
- Where
- South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Yonsei University
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to…
- Trial name
- NCT01589510
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Austria
- Volunteers
- 419 people
- Sponsor
- Allergan
Open Angle Glaucoma, Ocular Hypertension
Evaluation of Safety and Efficacy of PDP-716
The study will be conducted to evaluate the efficacy and safety of topical administration of PDP-716 compared with brimonidine tartrate ophthalmic solution.
- Trial name
- NCT03450629
- Testing
- Brimonidine Tartrate Ophthalmic Suspension, Brimonidine Tartrate Ophthalmic Solution
- Where
- 47 sites in United States
- Volunteers
- 682 people
- Sponsor
- Sun Pharma Advanced Research Company Limited
Glaucoma, Cataract
Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
The goal of this clinical trial is to further observe and learn if the SpyGlass Pharma Bimatoprost Implant System / IOL Combination works to treat cataracts and either ocular hypertension or glaucoma.
- Conditions
- Glaucoma, Cataract, Ocular Hypertension
- Trial name
- NCT07154810
- Where
- Honduras
- Volunteers
- 23 people
- Sponsor
- SpyGlass Pharma, Inc.
Open-angle Glaucoma
Expanded Access to Bimatoprost (Durysta)
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Durysta (Bimatoprost) prior to approval by the local regulatory agency.
- Trial name
- NCT05338606
- Testing
- Bimatoprost Sustained Release Implant
- Sponsor
- AbbVie